article thumbnail

One shot to stop HIV: MIT's bold vaccine breakthrough

Science Daily: Pharmacology News

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies.

Vaccine 227
article thumbnail

Left or right arm? New research reveals why vaccination site matters for immune response

Science Daily: Pharmacology News

Scientists have uncovered why vaccines can elicit a stronger immune response if they are administered in the same arm.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists engineer CRISPR enzymes that evade the immune system

Broad Institute

Researchers at the Broad Institute of MIT and Harvard and Cyrus Biotechnology have now engineered two CRISPR nucleases, Cas9 and Cas12, to mask them from the immune system. The engineered enzymes had similar gene-editing efficiency and reduced immune responses compared to standard nucleases in mice.

article thumbnail

New mRNA vaccine created to prevent and treat C. difficile

Science Daily: Pharmacology News

difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. In animal models, this first mRNA-LNP C.

Vaccine 290
article thumbnail

Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses

SCIENMAG: Medicine & Health

Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. Credit: Mike […]

article thumbnail

Nasal Spray COVID Vaccine Shows Promise in Early Trial

Drugs.com

11, 2023 -- New research points to the potential of a COVID-19 vaccine delivered through the nose. The phase 1 clinical trial showed that the product, administered nasally in two doses, delivered a significant immune response to. WEDNESDAY, Oct.

Vaccine 266
article thumbnail

Researchers design gene therapy that can effectively target glioblastoma

Science Daily: Pharmacology News

Immunotherapies, which mobilize the body's immune defenses against a cancer, have not been effective for GBM, in part because the tumor's surrounding environment is largely impenetrable to assaults from the body's immune system.

Therapies 186